Astrana Q1 revenue $404.4M (+20% YoY), net income $14.8M (+13%), EPS $0.31

Astrana Health, Inc.

2024-Q1 EPS reported $0.31 revenue$404,356,000

Total revenue $404.4M (+20% YoY); net income attributable $14.8M (+13%); diluted EPS $0.31 (+11%).
Adjusted EBITDA $42.2M (+42% YoY); full-year 2024 guidance reaffirmed: revenue $1.65-1.85B, adj. EBITDA $165-185M.
Completed largest acquisition (CFC) on Mar 31 and acquired PCCCV (~26K Medicaid members) on Mar 29.
Organic membership growth 10% YTD; total lives ~1M; full-risk capitation expected ~60% of total capitation revenue as of Apr 1.
Opened two new de novo clinics in Nevada in April.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Astrana Health, Inc. updated its first quarter ended March 31, 2024 guidance (reaffirmed).

Period: first quarter ended March 31, 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 7, 2024, Astrana Health, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024. A copy of the press release and supplemental data is furnished with this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Astrana Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-058018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.